The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own

Eli Lilly reported Q1 2026 revenue of $19.8 billion, up 56%, with net income rising 168% to $7.4 billion, while highlighting AI partnerships with OpenAI and Nvidia and a new weight-loss pill, Foundayo. Twist Bioscience posted fiscal Q2 2026 revenue of $110.7 million, up 19% for a 13th straight quarter, but its net loss widened to $44 million from $39.3 million. The article is broadly constructive on AI-driven drug development, but Twist remains higher-risk due to continued losses.

Analysis

The key market implication is not that AI is ‘helping pharma’ broadly, but that value is migrating from model owners to commercial execution layers with existing demand, regulatory pathways, and manufacturing scale. That structurally favors LLY over pure-enablement stories because AI can compress discovery time, but it cannot easily create distribution, payer access, or supply capacity — and those are the real bottlenecks in obesity. If the pill narrative gains traction, the second-order winner is not just unit growth but mix expansion into earlier-line, lower-friction prescribing, which could expand addressable population faster than consensus models currently assume.

TWST sits in a more asymmetric spot: it is effectively a leveraged tollbooth on AI hypothesis generation. The risk is that AI-driven target discovery increases experiment volume but not necessarily validated programs, which would produce more revenue growth without near-term margin inflection. Still, the Amazon Bio Discovery relationship matters because it can shorten sales cycles with biotech and pharma customers by embedding Twist into a workflow, making it harder for smaller competitors to displace once design-to-order DNA becomes part of a standardized pipeline.

The contrarian miss on LLY is that success may already be partly in the price, while the real upside is in duration, not multiple expansion. The stock can de-rate on any safety, access, or rebate headline even if AI continues to improve productivity; meanwhile, any manufacturing hiccup would be punished because expectations now assume seamless scale. For TWST, the consensus may be underestimating operating leverage if AWS materially increases order frequency, but the market is also right to discount profitability until it sees sustained gross margin improvement rather than just top-line momentum.

Key Decisions for Investors

• Long LLY vs short basket of slower-moving obesity/pharma peers for 6-12 months; thesis is that AI + formulation/product-cycle advantages favor the company with the clearest commercialization path and manufacturing scale.
• Initiate a tactical long TWST position on pullbacks, 3-6 month horizon, sized as a venture-style optionality trade; target upside if Amazon Bio Discovery drives visible order acceleration, but cap risk because earnings still look subsidy-like.
• Pair trade: long TWST / short a broad biotech index ETF over 6-9 months to isolate AI-enabled platform adoption versus sector beta; upside is cleaner if synthesis demand becomes workflow-embedded.
• For LLY holders, consider financed upside via call spreads rather than outright adds; near-term catalyst path is intact, but valuation leaves less room for disappointment on pricing or trial/supply headlines.
• Watch for any evidence of AI-driven hit rate improvement translating into shorter development cycles by 2H26; if not, reassess the entire ‘AI in drug discovery’ premium as mostly narrative rather than economic.